We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche’s Ocrevus Demonstrates Hints of Disease Modification, Cognitive Boost
Roche’s Ocrevus Demonstrates Hints of Disease Modification, Cognitive Boost
Ocrevus (ocrelizumab), Roche’s FDA-approved multiple sclerosis (MS) antibody, demonstrated hints of disease modification and cognitive benefit in phase 3b data that will be presented at the annual meeting of the American Academy of Neurology (AAN).